NASDAQ · Biotechnology

AKBA (AKBA) Stock

$1.31 -0.76% NASDAQ: AKBA Healthcare

Valuation

MetricValue
Price$1.31
Market Cap$351.42M
P/E Ratio-45.00
P/B Ratio7.33
P/S Ratio1.11
EPS (TTM)$-0.02
52-Week High$4.08
52-Week Low$0.82
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-15.15%
ROA-1.33%
ROCE69.70%
Gross Margin9.75%
Operating Margin9.75%
Net Margin-8.83%
Debt/Equity0.46
Current Ratio1.13

Annual Financials (USD)

Metric20212022202320242025
Revenue$212.0M$292.0M$195.0M$160.0M$236.0M
Operating Profit$-265.0M$-81.0M$-46.0M$-50.0M$23.0M
Net Profit$-282.0M$-94.0M$-52.0M$-69.0M$-5.0M
EPS$-1.48$-0.58$-0.28$-0.33$-0.02
Op Margin-125.0%-27.6%-23.8%-31.5%9.9%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$529.0M$356.0M$242.0M$221.0M$377.0M
Total Liabilities$455.0M$351.0M$272.0M$270.0M$344.0M
Cash$150.0M$90.0M$43.0M$52.0M$185.0M
Borrowings$136.0M$100.0M$104.0M$189.0M$216.0M

Latest News

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jul 2, 2026 Akebia Therapeutics, Inc. (AKBA) Strengthens Vafseo Patent Protection Through 2036 Insider Monkey · Jun 30, 2026 Akebia Therapeutics, US Renal Care Halt Kidney Disease Trial After Positive Interim Analysis MT Newswires · Jun 30, 2026 U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA GlobeNewswire · Jun 30, 2026 Akebia Therapeutics Secures New Patent Covering Dosing Regimen for Chronic Kidney Disease MT Newswires · Jun 10, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-253.0M$-73.0M$-23.0M$-41.0M$68.0M
Investing Cash Flow$40.0M$0$0$0$-8.0M
Financing Cash Flow$0$40.0M$0$-1.0M$0
Net Cash Flow$-79.0M$-59.0M$-49.0M$9.0M$133.0M
Free Cash Flow$-253.0M$-73.0M$-23.0M$-41.0M$68.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA11.37
FCF Yield23.23%
Quick Ratio1.33
Interest Coverage0.96
Return 1Y-69.58%
Return 3Y0.00%
Return 5Y-55.48%

Ownership

Insiders Held4.06%
Institutions Held42.10%
Institutions Float Held43.88%
Institutional HolderSharesReport Date
Blackrock Inc.18,693,2962026-03-31
State Street Corporation11,614,0062026-03-31
Vanguard Capital Management LLC11,166,7102026-03-31
Geode Capital Management, LLC6,452,2522026-03-31
Goldman Sachs Group Inc3,602,8272026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CMPX $1.89 -4.55% -4.71 $340.37M 0.00%
CRVS $13.31 +3.02% -23.00 $1.12B 0.00%
FDMT $10.09 -0.88% -3.47 $527.47M 0.00%
GOSSGossamer Bio, Inc. $0.19 +38.24% -0.17 $44.10M 0.00%
KALV $27.00 +0.00% -8.28 $1.44B 0.00%

About AKBA

AKBA is led by CEO John Butler, employs 181 people, headquartered in US, publicly traded since 2014.

AKBA stock trades at $1.31 with a market capitalization of $351.42M. The stock is valued at a price-to-earnings (P/E) ratio of -45.00, price-to-book of 7.33, price-to-sales of 1.11. Over the past 52 weeks the stock has ranged between $0.82 and $4.08, and currently trades 67.9% below its 52-week high.

On profitability, AKBA generates a return on equity (ROE) of -15.15%, return on capital employed of 69.70%, an operating margin of 9.75%, a net profit margin of -8.83%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides